论文部分内容阅读
目的探讨上皮性卵巢癌组织中P-糖蛋白(Pglycoprotein,P-gp)及Bcl-2(B细胞淋巴瘤/白血病-2)表达及与化疗和预后的关系。方法采用免疫组织化学技术法对原发性上皮性卵巢癌(Primary Epithelial Ovarian Cancer POEC)56例石蜡标本中P-gp和Bcl-2的表达进行测定,并分析患者的临床病理资料。结果 (1)POEC组织中p-gp的表达与术前化疗有关;Bcl-2表达与手术-病理分期、有无腹水、术前化疗有关;(2)化疗对P-gp阴性的有效率69.2%(18/26)高于P-gp阳性者20.0%(10/30);化疗对Bcl-2阴性有效率69.4%(16/23)高于阳性者的4.2%(8/33);(3)P-gp阳性表达组患者中位生存时间为42月,与P-gp阴性表达组患者(44月)比较,差异无统计学意义(P=0.707)。Bcl-2表达阳性的患者中位生存时间为37月,阴性的患者中位生存时间为62月,二者比较差异有统计学意义(P<0.05)。结论化疗可增加POEC组织中P-gp及Bcl-2表达的阳性率;P-gp及Bcl-2表达阳性者近期化疗疗效差。
Objective To investigate the expressions of P-glycoprotein (P-gp) and Bcl-2 (B-cell lymphoma / leukemia-2) in epithelial ovarian cancer and their relationship with chemotherapy and prognosis. Methods The expression of P-gp and Bcl-2 in 56 samples of primary Epithelial Ovarian Cancer POEC were detected by immunohistochemistry. The clinical and pathological data were analyzed. Results (1) The expression of p-gp in POEC tissues was related to preoperative chemotherapy. The expression of Bcl-2 was related to the surgical-pathological stage, with or without ascites and preoperative chemotherapy. (2) The effective rate of chemotherapy for P-gp negative was 69.2 % (18/26) were higher than that of P-gp positive patients (20.0%, 10/30); chemotherapy negative rate of Bcl-2 negative was 69.4% (16/23) higher than 4.2% (8/33) 3) The median survival time in patients with P-gp positive expression was 42 months, which was not significantly different from that in patients with P-gp negative expression (44 months) (P = 0.707). The median survival time of patients with positive expression of Bcl-2 was 37 months, and the median survival time of negative patients was 62 months. There was significant difference between the two groups (P <0.05). Conclusions Chemotherapy can increase the positive rate of P-gp and Bcl-2 expression in POEC tissues. The positive chemotherapy of P-gp and Bcl-2 patients is poor.